WALTHAM, Mass.--(BUSINESS WIRE)--
Interleukin Genetics, Inc. (OTCQB: ILIU.PK - News) announced today the publication of a peer-reviewed study which found that Interleukin-1 (IL-1) gene variations are associated with increased risk of periodontal disease. The study, which appears on the Journal of Periodontologys website, in advance of appearing in the print edition, was led by Nadeem Y. Karimbux, D.M.D., Associate Professor of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine.
The study assessed the potential value of IL-1 genetic variations in the risk for developing severe periodontal disease. The IL-1 genetic variations in the published study are included in Interleukin Genetics PST Genetic Test, the first genetic test to analyze genes for variations that identify an individuals predisposition for over-expression of inflammation and risk for periodontal disease. Researchers reviewed 27 published studies on IL-1 genetics and periodontal disease from 1997 through June 2011 which examined Caucasian adults, 35 years or older with adult periodontal disease, to determine whether there was a significant association between the presence of the IL-1 gene variations and the severity and progression of periodontal disease. Thirteen studies qualified for the quantitative meta-analysis, which found significant effects for the two individual gene variations (IL1A OR=1.48; and IL1B OR= 1.54) and for a composite genotype that combines minor alleles at each locus (OR= 1.51). Some heterogeneity was evident, but there was no indication of publication bias.
This review and meta-analysis show that IL1A and IL1B genetic variations are significant contributors to chronic periodontitis in Caucasians, said Dr. Karimbux. Having this actionable information can assist dentists in establishing more aggressive treatment protocols for patients at increased risk.
Periodontal disease is caused by a chronic bacterial infection that activates inflammation which destroys the gums and bone supporting the teeth. If left untreated, periodontitis leads to tooth loss. Studies have shown that people with chronic and prolonged inflammatory periodontal disease are at an increased risk of several systemic conditions, such as heart disease, strokes, rheumatoid arthritis and certain chronic pulmonary diseases.
Periodontal disease is one of the most common chronic diseases worldwide, but fortunately most individuals develop only a mild form of periodontitis that when caught early, can be easily treated. We now know that approximately 8 to 13 percent of the adult population will develop more destructive forms of periodontitis, and most of those at risk can be identified early based on smoking, IL-1 genetics and diabetes, said Kenneth Kornman D.D.S., PhD., study author and Chief Scientific Officer of Interleukin Genetics. While additional studies should be undertaken to look at specific periodontal conditions and additional ethnicities, this study reaffirms the role genetics plays in adult oral and overall health.
About Interleukin Genetics, Inc. Interleukin Genetics, Inc. (OTCQB: ILIU.PK - News) develops and markets a line of genetic tests under the Inherent Health and PST brands.The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics flagship products include its proprietary PST genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, Mass. and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit http://www.ilgenetics.com.
About PST The PST Genetic Test identifies individuals with increased risk for severe and progressive periodontal disease and significant tooth loss based on a proprietary panel of genetic variations that predispose an individual to over-express inflammation. In August 2010, Interleukin Genetics announced the initiation of a landmark clinical study on risk factors predictive of periodontal disease progression to tooth loss using a new version of the PST Genetic Test. This clinical studybeing conducted at the University of Michigan School of Dentistry and led by Dr. William Giannobile, Director of the Michigan Center for Oral Health Researchis designed to test whether risk factors, including genetic information, can guide more successful intervention and thus reduce the adverse outcomes of periodontal disease, such as tooth loss.
Certain statements contained herein are forward-looking statements, including statements that the clinical studies have the potential to expand the use of the PST Genetic Test. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in the Interleukin Genetics annual report on Form 10-K for the year ended December 31, 2010 and other filings with the Securities and Exchange Commission. Interleukin Genetics disclaims any obligation or intention to update these forward-looking statements.
See the rest here:
Newly Published Meta-Analysis Study Finds that IL-1 Gene Variations Contained in Interleukin Genetics’ PST Test are ...
Recommendation and review posted by G. Smith
